Member Announcement

PharmaNet/i3 to Present Scientific Posters at the 2012 American Association of Pharmaceutical Scientists (AAPS)

October 09, 2012 - PharmaNet/i3

PharmaNet/i3, inVentiv Health’s clinical segment, and a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced today that its scientists will present scientific posters on the Company’s broad bioanalytical capabilities at the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition being held from October 14-18 at McCormick Place in Chicago, IL.

 PharmaNet/i3 experts will be at booth 2412 to discuss the posters and the Company’s industry-leading bioanalytical capabilities, its custom method development and validation services, and the availability of more than 1000 validated assays.

Attendees are invited to learn more at the PharmaNet/i3 poster presentations:

Monday, October 15, 1:30 – 4:30pm

Optimization and Validation of an ELISA Kit for the Quantification of Four Interferon-beta (IFN- ß) Marketed Compounds in Human Serum (M1237)

A Robust and Sensitive UPLC/MS/MS Method for the Analysis of Insulin (M1230)

Tuesday, October 16, 9:30am – 12:30pm

Bioequivalence Assessment of Extended-release Products: Can Single-dose Data be Used to Predict Multiple-dose Study Outcome? (T2378)

Wednesday, October 17, 1:30 – 4:30pm

Irreproducibility of Results due to an Aromatic Hydroxylation of the Parent Drug into its Metabolite in Rat EDTA Plasma Acidified with Ascorbic Acid (W5250)

Quantifying Below the Endogenous Level for the Determination of Pyridoxal in Human Whole Blood by LC/MS/MS (W5256)

Highly Sensitive and Specific Assay for the Determination of Pyridoxine in Human Plasma by LC/MS/MS (W5276)

Reproducibility Issue for the Determination of Endogenous Level of Testosterone in Human Serum by LCMSMS (W5280)

Improved Chromatography for the Determination of Tibolone at Low Picograms Level in Human Plasma by LC/MS/MS (W5277)

Use of Surrogate in the Determination of Total Eicosapentaenoic Acid and Total Docosahexaenoic Acid in Human EDTA Plasma (W5278)

A Novel LCMSMS Method for the Determination of Free EPA and Free DHA in Stabilized Human Plasma (W5249)

Ultra Low Limit of Detection for Estradiol in Human Plasma by LC/MS/MS (W5270)

A Robust, Reproducible and Highly Sensitive Assay for the Determination of Fesoterodine and 5-Hydroxymethyl Tolterodine in Plasma by LC/MS/MS (W5251)

Automated Assays for the Determination of Leflunomide and Teriflunomide Human Plasma by LC/MS/MS (W5286)

About PharmaNet/i3
PharmaNet/i3, the inVentiv Health Clinical segment, is recognized as a leading provider of global drug development services to pharmaceutical, biotechnology, generic drug, and medical device companies, offering therapeutically specialized capabilities for Phase I-IV clinical development, bioanalytical services, and staffing from a single clinical professional to an entire functional team. For intelligent solutions needed to accelerate high quality drug development programs of all sizes around the world, PharmaNet/i3 works for you. For more information, visit www.pharmanet-i3.com.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv’s client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced and future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the impact of customer project delays and cancellations; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memorandums provided in connection with the issuance of our senior secured notes for further discussion of these risks and other factors.

Contact Information
Anne-Marie Hess
+1 609 951 6842
ahess@pharmanet-i3.com